ORDER OF BUSINESS

Reference Committee E (A-18)
Douglas Martin, MD, Chair

June 10, 2018
Regency Ballroom D
Hyatt Regency Chicago
Chicago

2. Board of Trustees Report 22 – In-Flight Emergencies (Resolution 516-A-17, Resolve 3)
3. Board of Trustees Report 30 – In-Flight Emergencies (Resolution 516-A-17, Resolve 5)
4. Resolution 524 – Naloxone on Commercial Airlines
6. Board of Trustees Report 38 – Timely Referral to Pain Management Specialist (Resolution 714-A-17)
9. Resolution 515 – Information Regarding Animal-Derived Medications
11. Resolution 526 – Direct-to-Consumer (DTC) Laboratory Testing
12. Resolution 505 – Researching Drug Facilitated Sexual Assault Testing
13. Resolution 506 – Non-Therapeutic Gene Therapies
14. Resolution 508 – Reintroduction of Mitochondrial Donation in the United States
15. Resolution 510 – Alcohol Use and Cancer
16. Resolution 513 – Hand Sanitizer Effectiveness
17. Resolution 514 – Effects of Virtual Reality on Human Health
18. Resolution 519 – Warning Labels for Children’s Digital and Video Games
19. Resolution 518 – Portable Listening Devices and Noise Induced Hearing Loss
20. Resolution 516 – Waste Incinerator Ban
23. Resolution 512 – Physician and Patient Education About the Risk of Synthetic Cannabinoid Use

Resolution 501 – Synthetic Cannabinoids

Note: Items in italics were originally placed on the reaffirmation consent calendar, were recommended against consideration, or were late items. At the beginning of the reference committee hearing, the chair will identify those items that will not be discussed in the hearing, and these items will NOT be considered by the reference committee.

During the reference committee hearing, supplemental materials may be sent to ReferenceCommitteeE@gmail.com or provided to the staff. Supplemental material includes items that have been referenced in testimony such as alternative wording, proposed amendments, supporting documents and the like. This email address is not intended as a means to provide testimony, which should be presented orally to the committee. This address is only operational for the duration of the reference committee hearings.
Resolution 509 – Opposing the Classification of Cannabidiol as a Schedule 1 Drug
25. Resolution 525 – Tramadol Change from DEA Schedule IV to Schedule III
26. Resolution 507 – Opioid Treatment Programs Reporting to Prescription Monitoring Programs
27. Resolution 511 – Education for Recovering Patients on Opiate Use After Sobriety
29. Resolution 523 – Biosimilar Interchangeability Pathway
30. Resolution 520 – Handling of Hazardous Drugs

Note: Items in italics were originally placed on the reaffirmation consent calendar, were recommended against consideration, or were late items. At the beginning of the reference committee hearing, the chair will identify those items that will not be discussed in the hearing, and these items will NOT be considered by the reference committee.

During the reference committee hearing, supplemental materials may be sent to ReferenceCommitteeE@gmail.com or provided to the staff. Supplemental material includes items that have been referenced in testimony such as alternative wording, proposed amendments, supporting documents and the like. This email address is not intended as a means to provide testimony, which should be presented orally to the committee. This address is only operational for the duration of the reference committee hearings.